Get the latest news, insights, and market updates on CNTA (Centessa Pharmaceuticals plc). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Centessa Pharmaceuticals (CNTA): Reviewing Valuation After 46% Three-Month Share Price Surge
Centessa Pharmaceuticals (CNTA) stock has quietly gained steam over the past quarter, delivering a 46% climb in that time. Investors may be looking beyond short-term volatility and focusing on the company’s long-term pipeline prospects and recent momentum. See our latest analysis for Centessa Pharmaceuticals. Centessa’s latest share price of $22.86 reflects a remarkable run, with a 45.7% share price return over the past quarter in addition to a 44.6% total shareholder return in the last year... Oct 17, 2025 - $CNTA
LifeSci Capital Reaffirms Buy Rating on Centessa Pharmaceuticals (CNTA) with a $39 PT, Anticipates Key Orexin Pipeline Data
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks with huge upside potential. On September 9, LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on Centessa Pharmaceuticals and set a price target of $39.00. In Q2 2025, Centessa Pharmaceuticals reported that the company had $404.1 million in cash and investments, which […] Sep 15, 2025 - $CNTA
Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Tuesday, September 9th at 4:50 PM ET. The live audio webcast of this event, as well as an archived recor Sep 3, 2025 - $CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all three indications this year with first-in-class potential in NT2 and IH ORX142 Phase 1 clinical trial for the treatment of select neurological and neurodegenerative disorders underway with data in acute Aug 12, 2025 - $CNTA
Centessa Pharmaceuticals Advances Neurological Drug ORX142 to Clinical Trials
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best low priced pharma stocks to buy now. On July 4, Nxera Pharma Co. Ltd., which develops and sells pharmaceutical products, announced that it is set to receive $4.8 million in milestone payments from Centessa Pharmaceuticals. These payments stem from their existing research collaboration and followed Centessa’s initiation […] Jul 15, 2025 - $CNTA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple